Evidence map›Paper›PMID 34876852›Full record

ArticleCancer management and research2021

Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience.

Andrew Schaefer, Ying Huang, Adam Kittai, Joseph E Maakaron, Caner Saygin, Jonathan Brammer, Sam Penza, Ayman Saad, Samantha M Jaglowski, Basem M William

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer management and research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Andrew SchaeferDepartment of Medicine, University of Wisconsin, Madison, WI, USA.
Ying HuangDepartment of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Adam KittaiDepartment of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Joseph E MaakaronDepartment of Medicine, University of Minnesota, Minneapolis, MN, USA.
Caner SayginDepartment of Medicine, University of Chicago, Chicago, IL, USA.
Jonathan BrammerDepartment of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Sam PenzaDepartment of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Ayman SaadDepartment of Internal Medicine, The Ohio State University, Columbus, OH, USA.ORCID 0000-0003-0003-0130
Samantha M JaglowskiDepartment of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Basem M WilliamOhioHealth Blood and Marrow Transplant Program, Columbus, OH, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Treatment with CD19 chimeric antigen receptor (CAR-T) cells, tisagenlecleucel and axicabtagene ciloleucel, has been associated with improved outcomes. Cytopenias were observed in clinical trials with both products; however, little is known regarding the patterns and outcomes of these cytopenias. SUBJECTS AND

methodsWe reviewed DLBCL patients (

resultsMedian duration of leukopenia, neutropenia, lymphopenia, anemia, and thrombocytopenia was 49, 9, 117.5, 125, and 95.5 days after CAR-T infusion, respectively. Filgrastim was used in 63% of patients, and 50% of patients received red cell or platelet transfusions. With the exception of neutropenia, increase in the duration of cytopenia of any lineage was associated with improvement in progression-free survival, and in overall survival in case of anemia. There was no association between the duration of cytopenias with either cytokine release syndrome or neurotoxicity. DISCUSSION: Our data suggest a correlation between cytopenias and survival outcomes after CD19 CAR-T therapy. If validated, cytopenia may be proven useful as a biomarker of response and survival after CAR-T therapy.

Indexed as

chimeric antigen receptor T-cellscytopeniasdiffuse large B-cell lymphomaimmunotherapytransformed follicular lymphomas

Identifiers

PMID34876852
PMCPMC8643129

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.